51. 全身性強皮症 Scleroderma Clinical trials / Disease details

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

425 trials found

diseases per page:

Showing 1 to 10 of 425 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03800017 (ClinicalTrials.gov)	September 1, 2022	21/11/2018	Skeletal Muscle Function in Interstitial Lung Disease	Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interst ...	Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis;Scleroderma;Non ...	Biological: Hyperoxia	University of British Columbia	NULL	Not yet recruiting	40 Years	80 Years	All	40	N/A	NULL
2	NCT04356287 (ClinicalTrials.gov)	April 2022	15/4/2020	Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis	Phase I/II Randomized Controlled Trial of Umbilical Cord-derived mesenChymAl stRomal cElls in System ...	Sclerosis, Systemic;Mesenchymal Stem Cells	Biological: UCMSC;Other: Placebo	Marie Hudson, MD	Assistance Publique - Hôpitaux de Paris;University Paris 7 - Denis Diderot;Université de Montréal;Me ...	Not yet recruiting	18 Years	N/A	All	18	Phase 1/Phase 2	NULL
3	NCT05214014 (ClinicalTrials.gov)	March 1, 2022	29/11/2021	Treatment of Systemic Sclerosis With Autologous Regulatory ?-cells	Treatment of Patients With Systemic Sclerosis With Autologous Regulatory ?-cells	Systemic Sclerosis	Biological: Autologous Regulatory ?-cells;Other: Standard treatment according to the clinical protoc ...	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	Belarusian State Medical University	Not yet recruiting	18 Years	80 Years	All	30	Phase 1/Phase 2	NULL
4	NCT05198557 (ClinicalTrials.gov)	March 2022	6/1/2022	A Study of MT-0551 in Patients With Systemic Sclerosis	Phase 3 Study of MT-0551 in Patients With Systemic Sclerosis (Placebo-Controlled Double-Blind Study) ...	Systemic Sclerosis	Drug: Inebilizumab;Drug: Placebo	Mitsubishi Tanabe Pharma Corporation	NULL	Not yet recruiting	20 Years	80 Years	All	80	Phase 3	Japan
5	NCT05236491 (ClinicalTrials.gov)	March 2022	10/2/2022	COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases	COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases	Rheumatoid Arthritis;Autoimmune Rheumatologic Disease;Systemic Lupus Erythematosus;Systemic Vasculit ...	Biological: COVID-19 vaccine	Paul R Fortin	Canadian Institutes of Health Research (CIHR)	Not yet recruiting	18 Years	N/A	All	287	Phase 2/Phase 3	NULL
6	JPRN-jRCT2031210521	15/02/2022	26/12/2021	Phase 3 Study of MT-0551 in Patients with Systemic Sclerosis	Phase 3 Study of MT-0551 in Patients with Systemic Sclerosis (Placebo-Controlled Double-Blind Study) ...	Systemic Sclerosis	(1)MT-0551 group Participants will receive intravenous (IV) inebilizumabon Day 1 and Day 15 of rando ...	Kondou Kazuoki	NULL	Pending	>= 20age old	<= 80age old	Both	80	Phase 3	Japan
7	NCT05214794 (ClinicalTrials.gov)	February 14, 2022	17/1/2022	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Syste ...	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Syste ...	Systemic Sclerosis	Drug: nemolizumab	Maruho Co., Ltd.	NULL	Not yet recruiting	20 Years	70 Years	All	8	Phase 2	Japan
8	NCT05016804 (ClinicalTrials.gov)	February 2022	17/8/2021	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Sys ...	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusio ...	Systemic Sclerosis	Biological: AlloRx	The Foundation for Orthopaedics and Regenerative Medicine	NULL	Recruiting	N/A	N/A	All	20	Phase 1	Antigua and Barbuda
9	EUCTR2020-005764-62-PL (EUCTR)	31/01/2022	05/01/2022	A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients w ...	A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Effic ...	Diffuse Cutaneous Systemic Sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10042953;Te ...	Product Code: HZN-825 INN or Proposed INN: HZN-825	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;Portugal;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;M ...
10	EUCTR2020-005764-62-NL (EUCTR)	31/01/2022	25/11/2021	A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients w ...	A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Effic ...	Diffuse Cutaneous Systemic Sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10042953;Te ...	Product Code: HZN-825 INN or Proposed INN: HZN-825	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;Portugal;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;M ...

First Previous1 2 3 4 5…43Next Last